Skip to main content
三元基因 logo

三元基因 — Investor Relations & Filings

Ticker · 920344 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2023-02-23 Earnings Release
Country CN China
Listing Beijing Stock Exchange 920344

About 三元基因

http://www.triprime.com/

Beijing Tri-Prime Gene Pharmaceutical Co., Ltd. is a biotechnology enterprise specializing in the research, development, production, and commercialization of modern genetic engineering pharmaceuticals. The company's core focus is on recombinant human interferon products, most notably Interferon ̑1b. This product is widely utilized in the treatment of viral diseases and malignant tumors, with a significant presence in the pediatric respiratory and hepatology markets. Tri-Prime Gene leverages advanced molecular biology and protein purification technologies to maintain its position as a leader in the interferon market. Its portfolio includes various formulations such as injections, sprays, and drops, designed to meet diverse clinical needs. The company continues to invest in innovative biopharmaceuticals, aiming to provide effective therapeutic solutions for infectious diseases and oncology.

Recent filings

Filing Released Lang Actions
2022年年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a 2022 annual performance express report (年度业绩快报公告), which indicates it is a preliminary earnings announcement for the full year 2022. It contains key financial data such as revenue, net profit, earnings per share, and asset figures, but explicitly states that the data are preliminary and unaudited, with final audited figures to be disclosed in the full annual report. The document is relatively short (1796 characters) and serves as a quick earnings update rather than a full annual report. This matches the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. Therefore, the correct classification is Earnings Release (ER). FY 2022
2023-02-23 Chinese
持股5%以上股东减持股份计划公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding a shareholder holding more than 5% of shares planning to reduce their stake. It details the shareholder's identity, the number and percentage of shares held, the planned reduction amount, methods, timing, and compliance with relevant stock exchange rules. This type of document is a notification about changes in major shareholding levels, specifically a reduction in significant share ownership. It does not contain financial statements or management discussion, nor is it a report or meeting material. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length is short and focused on shareholding changes, confirming this classification.
2023-02-13 Chinese
2022 年股权激励计划股票期权授予结果公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the results of a stock option grant under a 2022 equity incentive plan by Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It details the number of options granted, the recipients, exercise price, exercise conditions, and the impact on financials. It is a formal disclosure of the stock option grant results, including detailed tables of recipients and terms. This type of document is a regulatory announcement about capital changes related to share-based compensation, specifically the granting of stock options. It is not a full financial report, audit report, or management discussion, nor is it a voting result or a proxy statement. The document fits best under the category of Share Issue/Capital Change (SHA), as it announces the issuance of stock options as part of the equity incentive plan.
2023-01-08 Chinese
上海荣正企业咨询服务（集团）股份有限公司关于北京三元基因药业股份有限公司2022年股权激励计划首次权益授予相关事项之独立财务顾问报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report" related to the "2022 Equity Incentive Plan First Grant" of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It contains detailed sections including definitions, statements, assumptions, independent financial advisor opinions, approval procedures, grant conditions, grant details, and impact on financial results. The document is substantive and over 8,000 characters, indicating it is a full report rather than a brief announcement. The content focuses on the equity incentive plan, its approval, and financial implications, which aligns with a detailed advisory or audit-related report rather than a general annual or quarterly report. It is not a simple announcement or proxy solicitation but a detailed independent financial advisor report on a specific equity incentive plan grant. This type of document fits best under the category of Audit Report / Information (AR), as it is a standalone advisory report related to financial and regulatory compliance matters concerning the equity incentive plan, not a full annual report or earnings release. FY 2022
2022-11-20 Chinese
北京浩天律师事务所关于北京三元基因药业股份有限公司2022年股权激励计划首次授予相关事项的法律意见书
Regulatory Filings
2022-11-20 Chinese
2022 年股权激励计划首次授予激励对象名单（授予日）
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Beijing Sanyuan Gene Pharmaceutical Co., Ltd. regarding the 2022 equity incentive plan and the initial list of incentive recipients. It includes detailed allocation of stock options to directors, senior management, and core employees. The document is an announcement of a stock-based compensation plan, which relates to share-based incentives for employees and executives. It is not a financial report, earnings release, or management discussion. It is also not a regulatory filing about voting results or capital changes but specifically about the equity incentive plan and the list of recipients. This type of document fits best under the category of Capital/Financing Update (CAP), as it relates to company financing activities through equity incentives.
2022-11-20 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.